Psyence Biomedical (PBM) EBT (2023 - 2025)

Psyence Biomedical (PBM) posted quarterly EBT of -$1.5 million for Q3 2025, down 230.18% year-over-year from $1.2 million in Q3 2024, and down 230.18% on a QoQ basis from $1.2 million in Q3 2024.

Psyence Biomedical (PBM) EBT (2023 - 2025) Analysis & Trends

Psyence Biomedical (PBM) has reported EBT for 3 consecutive years, with -$1.5 million the latest figure, recorded in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT (Qtr)
1 Genmab A 276,399.99 Bn 276,398.47 Bn 831.00 Mn 74.00 Mn
2 Akari Therapeutics 1,217.26 Bn 1,217.26 Bn - -15.31 Mn
3 BeOne Medicines 419.38 Bn 414.59 Bn 1.35 Bn 259.22 Mn
4 Vertex Pharmaceuticals 126.54 Bn 119.30 Bn 2.59 Bn 1.25 Bn
5 Pharming 110.17 Bn 110.12 Bn 65.80 Mn -4.91 Mn
6 Regeneron Pharmaceuticals 64.97 Bn 56.22 Bn 3.31 Bn 831.20 Mn
7 Argenx Se 56.44 Bn 56.44 Bn 1.18 Bn 438.00 Mn
8 Alnylam Pharmaceuticals 40.09 Bn 37.08 Bn 959.66 Mn 221.65 Mn
9 Revolution Medicines 37.15 Bn 37.15 Bn - -453.82 Mn
10 Psyence Biomedical 1.72 Mn 1.72 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2025 -1.50 Mn
Sep 30, 2024 1.16 Mn
Mar 31, 2023 -3.23 Mn